CDC: R292K Substitution and Drug Susceptibility of Influenza A(H7N9) Viruses

Emerging Infectious Diseases
Ahead of Print

Volume 19, Number 9—September 2013 

Katrina Sleeman¹, Zhu Guo¹, John Barnes, Michael Shaw, James Stevens, and Larisa V. Gubareva 

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

 

Abstract

Neuraminidase inhibitors are the only licensed antiviral medications available to treat avian influenza A(H7N9) virus infections in humans. According to a neuraminidase inhibition assay, an R292K substitution reduced antiviral efficacy of inhibitors, especially oseltamivir, and decreased viral fitness in cell culture. Monitoring emergence of R292K-carrying viruses using a pH-modified neuraminidase inhibition assay should be considered.

Continued:  http://wwwnc.cdc.gov/eid/article/19/9/13-0724_article.htm